Why the study?
Does dexrazoxane reduce cardiotoxicity and affect the risk of second malignant neoplasms in children receiving anthracycline chemotherapy?
Population
Children receiving anthracycline chemotherapy
Design
Meta-analysis
Authors
Loading...
Supports individualized dexrazoxane use to reduce cardiotoxicity in children on anthracyclines; extends evidence on borderline SMN risk trade-off.
Does dexrazoxane reduce cardiotoxicity and affect the risk of second malignant neoplasms in children receiving anthracycline chemotherapy?
Dexrazoxane reduces cardiotoxicity in children receiving anthracyclines but may carry a borderline increased risk of second malignant neoplasms, requiring individualized risk-benefit assessment.
Shaikh et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: